U-SPECT 7 CT from MILabs (a Rigaku company) offers unmatched preclinical dynamic and whole body Single Photon Emission Computed Tomography (SPECT) performance, integrated with diagnostic micro-CT.
This e-learning module aims to provide an update for the specialists in Nuclear Medicine on the current modalities for performing and interpreting SPECT/CT during bone scintigraphy with 99m Tc-labeled ...
Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC). Total and anatomically contextualized quantitative 18F-DCFPyL PET at ...
GE HealthCare has announced that the Food and Drug Administration has granted clearance for its Aurora nuclear medicine system and Clarify DL, an AI-powered deep learning image reconstruction ...
Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...
A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong ...
U-SPECT 7 CT from MILabs (a Rigaku company) offers unmatched preclinical dynamic and whole-body Single Photon Emission Computed Tomography (SPECT) performance, integrated with diagnostic micro-CT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results